In vivo models have demonstrated that interleukin-13 (IL-13) plays an important role in asthma. However, few studies have evaluated the effect of inhibition of IL-13 on established and persistent disease. In the present study we have investigated the effect of a therapeutic dosing regimen with an anti-IL-13 monoclonal antibody (mAb) in a chronic mouse model of persistent asthma. Balb/c mice were sensitized to allergen (ovalbumin, OVA, on days 1 and 8) and challenged with OVA weekly from day 22. Anti-IL-13 mAb or vehicle dosing was initiated following two OVA challenges when disease was established. At this time, mice exhibited airway hyperresponsiveness (AHR), increased mucus production, inflammation and initiation of subepithelial fibrosis compared to saline-challenged mice. Mice received four additional OVA challenges. Treatment with anti-IL-13 mAb inhibited AHR and prevented the further development of subepithelial fibrosis and progression of inflammation. Furthermore, mAb treatment reversed the mucus hyperplasia to basal levels. These effects were associated with an inhibition of cytokines, chemokines and matrix metalloproteinase-9. These data demonstrate that neutralization of IL-13 can inhibit the progression of established disease in the presence of repeated allergen exposures.
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Mice deficient in the IL-13 (and IL-4) signaling molecule signal transducer and activator of transcription 6 (STAT6) fail to develop allergen-induced AHR and mucus hyperplasia (Kuperman et al., 2002) . Finally, utilization of an IL-13-specific neutralization strategy with soluble IL-13 receptor fusion protein (sIL-13Ra2Fc) has demonstrated the pivotal role of this cytokine in experimental allergen (ovalbumin; OVA)-induced airway disease (Grunig et al., 1998; Wills-Karp et al., 1998; Taube et al., 2002) .
Clinically, therapeutic interventions occur in the presence of established disease. To date, experimental therapeutic-intervention studies have not investigated the effects of IL-13 neutralization in the presence of chronic, persistent allergen challenges. In the present study, we used a rat monoclonal antibody (mAb) to neutralize the actions of mouse IL-13 specifically and have initiated treatment with the mAb once disease is established.
Further, we have continued mAb treatment in the presence of further allergen challenges.
Our data demonstrate that anti-IL-13 mAb treatment inhibits AHR, chronic inflammation, subepithelial fibrosis and reverses mucus hyperplasia. Associated with these effects, neutralization of IL-13 inhibited the production of multiple cytokines, chemokines and matrixmetalloproteinase 9 (MMP-9). These data support the hypothesis that IL-13 is an important upstream mediator involved in asthma pathogenesis and disease progression.
Substrate development was stopped by addition of 4N sulfuric acid and the optical density determined at 490nm.
In vitro bioactivity of CNTO 134
Neutralization activity of CNTO 134 was measured by determining inhibition of rm IL-13-mediated B9 myeloma cell (a murine B cell hybridoma cell line, ATCC, Rockville, MD) proliferation. B9 cells were maintained in IMDM (containing 5% fetal bovine serum (FBS), 1% l-glutamine, 0.1 mM MEM nonessential amino acids, sodium pyruvate, 50 µM 2-mercaptoethanal and 5 ng/ml rm IL-13 (R&D Systems). 1X10 5 B9 cells/ml (50 µl/well) cells were seeded in 96-wells culture plates and incubated with a final concentration of 5 ng/ml of mouse IL-13 together with different concentrations of CNTO 134 for 3 days at 37 0 C, 5%CO 2 . The IL-13-dependent cell proliferation was measured using a luminescent ATP detection assay kit (Packard Bioscience, Meriden, CT).
Inhibition of IL-13 resulted in lowered proliferation of B9 cells that could be measured based on the amount of ATP per well. The concentration of CNTO 134 that inhibited B9 cell proliferation by 50% (IC50) was 17 ng/ml (data not shown).
In vivo OVA model protocol
Mice were immunized intraperitoneally (I.P.) with 10 µg OVA (Sigma, St. Louis, MO) in 100 µl of PBS mixed with the same volume of Inject Alum (Pierce, Rockford, IL) on day 1, and boosted in the same way on day 8. On day 22, 29, 36, 43, 50 and 52, mice received an intranasal (I.N.) challenge with 50 µl PBS or 100 µg OVA (2 mg/ml) under ketamine/xylazine anesthesia (90 and10 mg/kg respectively; I.P.). Rat anti-mouse IL-13
This article has not been copyedited and formatted. The final version may differ from this version. 
Airway hyperresponsiveness (AHR)
On day 36 and 53 AHR was measured in mice using whole body plethysmography (Buxco, Sharon, CT). AHR was measured following aerosolization of PBS followed by increasing concentrations of methacholine (10-40 mg/ml, Sigma) for two minutes into the chamber. AHR was expressed as the average enhanced pause (Penh) (Hamelmann et al., 1997) that was measured over a five minute period following aerosol exposure to PBS or methacholine. All mice were exposed to PBS and subsequently exposed to each methacholine dose. There was approximately an interval of sixty minutes between each aerosol exposure and within this period of time the Penh values had returned to baseline.
Bronchoalveolar lavage (BAL)
After AHR measurements, mice were euthanized (CO2 asphyxiation), the trachea cannulated and BAL was performed by slowly injecting 1 ml of PBS (once) into the trachea and the lavage was retrieved. Supernatants were collected after centrifugation This article has not been copyedited and formatted. The final version may differ from this version. (10 minutes; 1500 rpm) for further analyses. BAL cells were resuspended in 1 ml PBS (containing 2% FCS) for total and differential cell counts.
Histology and morphometric analyses
Following BAL, the right lung was clamped off and removed and, the left lung was fixed with 10% buffered formalin under constant pressure of 15 cm water. After fixation, lungs were dehydrated and embedded in paraffin by routine methods. Lungs were oriented in the blocks so that para-hilar sagital sections were obtained. Five micron serial sections were stained with hematoxylin and eosin (H&E), periodic acid Schiff (counterstained with hematoxylin) (PAS) or picric-Sirius Red (SR). H&E stained sections were used for general evaluation of histopathologic change and PAS for morphometric analysis of mucus inclusions and inflammatory infiltrates. SR, viewed and photographed under crossed polarized light, was used for morphometric analysis of mature collagen fibers (Dolhnikoff et al., 1999) . For semi-quantitiative analysis of mucus inclusions, cellularity and mature collagen, sections were analyzed morphometically using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD). PAS stained sections were threshholded so as to measure only the area of mucus. H&E sections were thresh-holded so as to measure all nuclei. This can be taken as a measure of cellularity. To calculate the % lung occupied by mucus or nuclei (equation 1), the stained area for each constituent was divided by the total area of lung (including blood vessels and air space) included in the 4x field:
This article has not been copyedited and formatted. The final version may differ from this version. To measure mature collagen, Sirius red stained sections were photographed with crosspolarized light, the images converted from RGB to hue-saturation-intensity (HIS). These images were thresh-holded so as to measure only mature, i.e., birefringent, collagen and the integrated optical density (IOD) for collagen measured for each 4x field. A random, low magnification 4x objective field, of the para-hilar region, including the main stem bronchus and its primary and secondary branches, was photographed for each lung using a Nikon E800 equipped with plan apochromatic lenses and a Nikon DXM1200 digital camera. Images were stored as red green blue (RGB).tiff files for morphometric analysis.
Chemokine, cytokine and MMP-9 detection by ELISA
The right lungs from some mice were homogenized in PBS and supernatants assayed chemokines, cytokines (R&D Systems, Minneapolis, MN) and total MMP-9 (Amersham Biosciences, Piscataway, NJ).
Statistical analysis
Data are summarized using mean ± standard error of the mean (S.E.M.). Statistical differences between groups were tested based on analysis of variance (ANOVA) with two-tailed tests. For day 36 AHR, data analyses for significant differences within the entire data set were performed on means and S.E.M. across both days 36 and 53.
Comparisons between the groups of animals (both PBS groups versus both OVA groups;
Group 1 and 3 versus Group 2 and 4) were made at all three methacholine concentrations This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Neutralization of IL-13 reverses established AHR
It was important to establish the presence of airway disease at the time CNTO 134 treatment was initiated. Disease was induced in mice, following OVA sensitization, with two allergen challenges a week apart (outlined in Figure 1 ). One week after the second allergen challenge (day 36) a small subset of mice was analyzed for the presence of allergic disease. AHR to methacholine challenge was observed in mice challenged with OVA compared to PBS-challenged mice (Table 1) . Anti-IL-13 treatment was initiated on day 36 and mice continued to receive multiple allergen challenges. Treatment with CNTO 134 inhibited AHR on day 53 (Figure 2 ).
Neutralization of IL-13 inhibits the progressive increase in BAL inflammation and cellularity in lung tissue
Two OVA challenges also induced an increase in the numbers of eosinophils, mice. Similarly, there was still evidence of airway smooth muscle cell hypertrophy. As was seen in the PBS-treated OVA-challenged mice, the inflammatory infiltrates accounted for the majority of lung cellularity.
Neutralization of IL-13 reverses excessive mucus production
Lung histology revealed a significant increase in mucus staining in allergen-challenged 
Neutralization of IL-13 inhibits the development of fibrosis
IL-13 regulates MMP-9 activity and production of pro-inflammatory mediators
Airway remodeling is associated with MMP activity. To address whether IL-13 was involved in MMP activation, total MMP-9 protein levels was measured in the lung tissue of mice ( Figure 6 ). Significant increases in MMP-9 were observed in OVA-challenged mice on day 53. Neutralization of IL-13 resulted in a reduction in MMP-9. A number of cytokines and chemokines were also modulated with anti-IL-13 treatment. Allergen challenges induced significant increases in the levels of interleukin (IL-)-4, -5, -13, tumor necrosis factor α (TNFα), KC and eotaxin by day 36 and these levels remained elevated on day 53 together with significant increases in JE levels (Table 2) . Eotaxin levels increased further on day 53 compared to levels present on day 36. This may reflect the progressive increase in eosinophils in the BAL between the two time points.
Neutralization of IL-13 inhibited the levels of all cytokines and chemokines. The effect of CNTO 134 on IL-13 protein levels was not assessed since CNTO 134 interfered with the ELISA assay.
DISCUSSION
The current study has demonstrated that an IL-13-specific neutralization approach with a mAb may be an effective therapy for the treatment of asthma. To our knowledge, this is the first demonstration that therapeutic dosing with an anti-IL-13 mAb in established, persistent, progressive disease in mice modulated lung function as well as the underlying This article has not been copyedited and formatted. The final version may differ from this version. A trend towards inhibition of BAL neutrophilia was also observed. The effect of IL-13 inhibition on allergic inflammation is controversial (Grunig et al., 1998; Wills-Karp et al., 1998; Taube et al., 2002) and studies (including the current study) suggest that neutralization of IL-13 may impact the inflammatory response in more chronic settings (Taube et al., 2002) . Data also suggest that IL-13 may play a protective role in acute inflammatory settings. IL-13 has been shown to be anti-inflammatory in a guinea pig model of acute allergic inflammation (Watson et al., 1999) . Further, neutralization of IL-13 resulted in an exacerbation of inflammation in an experimental model of acute lung injury (Lentsch et al., 1999) .The allergen challenge protocol used in the present study differs significantly from previous studies: at the time mAb treatment was initiated persistent disease and pathology was established and mice continued to receive multiple allergen challenges to establish a chronic disease state. The discrepancy in data regarding an effect on cell inflammation may be due to differences in the mouse strain used, the time point at which cell numbers were evaluated together with the chronicity of the model. Since neutralization of IL-13 reduced the levels of the eosinophil-survival Table 2 . All mice were sensitized to OVA. On day 36 and 53 lungs were homogenized and supernatants were analyzed for levels of cytokines (IL-13, IL-4, IL-5, TNFα) and chemokines (eotaxin, KC and JE) as described in Methods. On day 36, lungs were collected from mice one week after the second PBS (n=4) or OVA challenge (n=6). On day 53, lungs were collected 24 h following the last PBS (n=10) or OVA challenge where mice were either treated with i.v. vehicle (OVA/vehicle; n=13) This article has not been copyedited and formatted. The final version may differ from this version.
